BioSpace News Archive

Three of the top ten pharmaceutical companies, multiple biotechnology companies, Stanford’s Cell Therapy Clinic and Moffitt Cancer Center are initial participants.

IQVIA™, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, announced that Laboratoires Théa, the leading independent eye care group in Europe, has selected IQVIA Technologies’ Orchestrated Customer Engagement platform and the OneKey HCP/HCO reference database for deployment across more than 22 markets.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer leadership at the 39 th Annual J.P. Morgan Healthcare Conference to be held virtually. Albert Bourla, Chairman and Chief Executive Officer, will participate in a fireside chat presentation on Tuesday, January 12, 2021 at 10:00 a.m. EST. Angela Hwang, Group President, Pfizer Biopharmaceuticals Group, wi

Sensory Cloud, a Cambridge-based health technology start-up and maker of FEND, and Bangalore Baptist Hospital (India), today announced new research published in the Molecular Frontiers Journal highlighting the effectiveness of the FEND

Nephros, Inc. announces the granting of a patent that covers technology utilized in HDF2, and announces expanded heat disinfection product capabilities.

Biocare Medical, LLC, a leading provider of innovative immunohistochemistry (IHC) instrumentation and reagents, announces the release of the fully automated staining platform ONCORE Pro™ for IHC and ISH applications.

Pharmaleads, a biopharmaceutical company specialized in the development of innovative pain relief products, announces the promotion of Tanja Ouimet as Chief Operating Officer and Hervé Poras as Chief Scientific Officer.

NAMSA ® Acquires Syntactx to Enhance End-to-End CRO Development Solutions, Expanding Medical Device Clinical Research Capabilities and Expertise TOLEDO, Ohio & NEW YORK--( BUSINESS WIRE )-- NAMSA , the world’s only 100% medical device-focused Contract Research Organization (CRO) providing full continuum development solutions, announced today its acquisition of New York-based CRO, Syntactx . This acquisition follows independent healthcare investment fir

Vancouver, British Columbia--(Newsfile Corp. - January 5, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the “Company” or “PreveCeutical”), is pleased to announce it has filed a provisional application at the Australian Patent Office on December 22, 2020, entitled “Cyclic Peptides and Uses Thereof”, application number 2020904798, with the aim of seeking protection for certain cyclic peptides and their use in prevention and treatment of brain cancer.

Median Technologies, The Imaging Phenomics Company® announces the publication date for its 2020 results